Trevi Therapeutics, Inc. - Common Stock (TRVI)

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant results at multiple doses.

In today's session, these stocks are experiencing unusual volume.

The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.